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Abstract
Rationale Asenapine, a novel psychopharmacologic agent
in the development for schizophrenia and bipolar disorder,
has high affinity for serotonergic, α-adrenergic, and
dopaminergic receptors, suggesting potential for antipsy-
chotic and cognitive-enhancing properties.
Objectives The effects of asenapine in rat models of
antipsychotic efficacy and cognition were examined and
compared with those of olanzapine and risperidone.
Materials and methods Amphetamine-stimulated locomo-
tor activity (Amp-LMA; 1.0 or 3.0 mg/kg s.c.) and
apomorphine-disrupted prepulse inhibition (Apo-PPI;
0.5 mg/kg s.c.) were used as tests for antipsychotic activity.
Delayed non-match to place (DNMTP) and five-choice
serial reaction (5-CSR) tasks were used to assess short-term
spatial memory and attention, respectively. Asenapine doses
varied across tasks: Amp-LMA (0.01–0.3 mg/kg s.c.),
Apo-PPI (0.001–0.3 mg/kg s.c.), DNMTP (0.01–0.1 mg/kg
s.c.), and 5-CSR (0.003–0.3 mg/kg s.c.).
Results Asenapine was highly potent (active at 0.03 mg/kg)
in the Amp-LMA and Apo-PPI assays. DNMTP or 5-CSR
performance was not improved by asenapine, olanzapine, or
risperidone. All agents (P<0.01) reduced DNMTP accuracy at
short delays; post hoc analyses revealed that only 0.1 mg/kg
asenapine and 0.3 mg/kg risperidone differed from vehicle.
All active agents (asenapine, 0.3 mg/kg; olanzapine, 0.03–
0.3 mg/kg; and risperidone, 0.01–0.1 mg/kg) significantly
impaired 5-CSR accuracy (P<0.05).
Conclusions Asenapine has potent antidopaminergic
properties that are predictive of antipsychotic efficacy.
Asenapine, like risperidone and olanzapine, did not
improve cognition in normal rats. Rather, at doses greater
than those required for antipsychotic activity, asenapine
impaired cognitive performance due to disturbance of
motor function, an effect also observed with olanzapine
and risperidone.
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Introduction
Although antipsychotics are effective in controlling the
psychotic or positive symptoms of schizophrenia, they have
limited efficacy in the treatment of negative or cognitive
symptoms. In addition, most of the currently used drugs are
associated with poor tolerability, which contributes to high
rates of treatment discontinuation (Lieberman et al. 2005).
Thus, it is clear that there is a continued need for new
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ity. Asenapine is a novel psychopharmacologic agent being
developed for the treatment of schizophrenia and bipolar
disorder. It has a unique signature of human receptor
binding that is characterized by strong affinity and
antagonism at serotonergic, dopaminergic, α-adrenergic,
and histamine receptor subtypes (Shahid et al. 2009). In
particular, it has high activity toward a broad range of
serotonin (5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, and 5-HT7)
receptors, which may aid efficacy. Indeed, emerging
clinical data show that asenapine is effective in treating
both positive and negative symptoms of schizophrenia
(Potkin et al. 2007), mania in bipolar disorder patients
(McIntyre et al. 2008) with preliminary indications for
cognitive deficits in patients with schizophrenia (Fleming et
al. 2007, abstract).
The efficacy of antipsychotic agents in treating the
positive symptoms of schizophrenia is related in large part
to their antagonism of dopamine D2 receptors (Kapur and
Mamo 2003; Remington 2003). As a result, reversal of
amphetamine-stimulated locomotor activity (Amp-LMA)
and reversal of apomorphine-induced deficits in prepulse
inhibition (Apo-PPI) have been used as animal models of
antipsychotic efficacy (Geyer et al. 2001; Nakai et al. 2008;
Nordquist et al. 2008; Varty and Higgins 1995). In the
Amp-LMA model, the magnitude of inhibition induced by
atypical and typical antipsychotics differs as a function of
the dose of amphetamine administered (Arnt 1995).
Therefore, the differential inhibition of Amp-LMA by
antipsychotics as a function of amphetamine dose can be
used to assess the “atypicality” of novel antipsychotic
agents, just as higher affinity for 5-HT receptors relative to
D2 receptors can be used. The PPI model operationally
indexes sensorimotor gating by assessing the ability of a
weak stimulus to inhibit the response to a startle stimulus,
which can be disrupted by dopamine receptor agonists. The
ability of a pharmacologic treatment to reverse deficits in
PPI induced by dopaminergic agents, such as amphetamine
and apomorphine, has also been used to assess antipsy-
chotic activity.
Schizophrenia is associated with an array of cognitive
deficits that are evident and substantially unaltered even
when positive symptoms of schizophrenia are effectively
controlled (Sharma and Antonova 2003). Cognitive deficits
are now recognized as a core element of the disorder and
are believed to have significant bearing on the patient's
recovery and reintegration into society (Addington et al.
2001; Cuesta et al. 2001). The importance of animal models
for assisting in the identification of antipsychotic com-
pounds with cognitive-enhancing properties is becoming
increasingly recognized (Hagan and Jones 2005). However,
preclinical investigations face challenges that include
determining the most appropriate model, translating obser-
vations to the clinical setting, and addressing whether
challenging a normal animal to the limits of its capabilities
or inducing deficits thought to mimic a component of the
pathologic condition is more appropriate. There are several
well-established animal models that can be used to
investigate cognitive function in the rodent. The delayed
non-match to place (DNMTP) and five-choice serial
reaction (5-CSR) tasks are commonly used to assess
short-term spatial memory and sustained attention, respec-
tively, and are sensitive to pharmacologic interventions that
improve cognition (Amitai N and Markou 2009; Quarta et
al. 2007; Sukhotina et al. 2008; Ward et al. 2004).
Given the potent antidopaminergic activity of asenapine
and its relatively higher affinity for a broad range of
serotonergic and α-adrenergic receptors, we hypothesized
that asenapine may have a psychopharmacologic profile
combining potent antipsychotic action with the potential to
attenuate aspects of the cognitive deficits associated with
schizophrenia. In the current report, the effects of asenapine
were assessed in rats in tests of antipsychotic efficacy
(Amp-LMA and Apo-PPI) and cognitive function (DNMTP
and 5-CSR). The aim was to compare doses producing
antipsychotic efficacy with those having effects on cogni-
tive function.
Materials and methods
Animals
Studies were conducted in three laboratories using two
strains of male rats. Sprague–Dawley rats were used in the
Amp-LMA (130–150 g, Harlan, Inc., Indianapolis, IN,
USA) and Apo-PPI studies (250–325 g, Harlan, Inc., San
Diego, CA, USA). Lister Hooded rats (300–400 g, Harlan
UK Limited, Oxon, UK) were used in the DNMTP and 5-
CSR studies. All rats were group-housed (two to four per
cage) and maintained on a 12-h light–dark cycle (lights on
at 6–7A.M.). Ad libitum food and water access was available
during the Amp-LMA and Apo-PPI studies, except for
intermittent 24-h periods before drug testing in the Amp-
LMA study. In the DNMTP and 5-CSR studies, food
availability was restricted in order to maintain the rats at
approximately 85% of their predicted free-feeding body
weight. To achieve this, animals were weighed daily, and
the quantity of lab chow given to each cage adjusted. If an
individual animal diverged significantly from the pattern of
his cagemates the animal would be separated temporarily
during the feeding period to allow either a proportionately
higher or lower food allowance to be accessed.
The Amp-LMA and Apo-PPI studies were approved by
the respective Institutional Animal Care and Use Commit-
tees and were conducted in accordance with the National
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Laboratory Animals (Institute of Laboratory Animal
Resources 1996). The DNMTP and 5-CSR studies were
conducted in accordance with the 1986 UK Animals
(Scientific Procedures) Act.
Drugs
Asenapine (Schering-Plough, Newhouse, Lanarkshire, UK)
was administered subcutaneously (s.c.) in all studies. The
doses administered were consistent with previously pub-
lished studies in rats (Franberg et al. 2008; Huang et al.
2008; Tarazi et al. 2008) and encompassed a range that
approximates clinically relevant D2 receptor occupancy
levels (Schotte et al. 1996). Olanzapine and risperidone
(Pfizer Inc., Ann Arbor, MI, USA for the Amp-LMA
studies; Schering-Plough for the DNMTP and 5-CSR
studies) doses were selected based on previous publications
(Abdul-Monim et al. 2006; Amitai et al. 2007; Arnt 1995;
Didriksen et al. 2007; Grayson et al. 2007; Wolff and
Leander 2003). Haloperidol and apomorphine were
obtained from Sigma-Aldrich (St. Louis, MO, USA) for
the Amp-LMA and Apo-PPI studies.
In the LMA study, asenapine (0.01–0.3 mg/kg s.c.) was
suspended in 1% cremophor EL, 1% HCl 1 N, and 0.5%
methocel in saline; olanzapine (1.0–10.0 mg/kg oral
gavage) and risperidone (0.1–3.0 mg/kg oral gavage) were
suspended in 1% cremophor EL, 1% HCl 1 N, and 0.5%
methocel in water. Haloperidol (0.1–1.0 mg/kg oral gavage)
was dissolved in 1% lactic acid in water. D-Amphetamine
(1.0 or 3.0 mg/kg s.c.) was dissolved in 0.9% saline.
In the Apo-PPI studies, asenapine (0.001–3.0 mg/kg s.
c.) was dissolved in 0.9% saline, and apomorphine
(0.5 mg/kg s.c.) was dissolved in 0.9% saline containing
1 mg/mL ascorbic acid. Both were administered in a
volume of 1 mL/kg.
In the DNMTP and 5-CST studies, asenapine (0.003–
0.3 mg/kg s.c.), olanzapine (0.03–0.3 mg/kg s.c.), and
risperidone (0.01–0.3 mg/kg s.c) were prepared in a 5%
mulgofen/saline solution.
Procedures
Study 1: spontaneous and amphetamine-stimulated
locomotor activity
Activity was assessed using 16-Beam Digiscan Animal
Activity Monitors (Accuscan Instruments Inc.; Columbus,
OH, USA). Each activity monitor consisted of a
Plexiglas® box (16×16 in.) that was housed inside a
stainless steel, ventilated, sound-attenuating chamber.
Horizontal beam breaks were converted to distance
traveled (centimeter).
Spontaneous LMA was assessed in 5-min intervals
during a 30-min session. The chamber was darkened to
maximize spontaneous activity. Rats were treated with
asenapine 30 min before assessment; olanzapine, risper-
idone, or haloperidol was administered 60 min before
assessment.
Amp-LMAwas assessed in 5-min intervals during a 120-
min session. The chamber was illuminated to minimize
spontaneous activity. For asenapine testing, rats were
placed into the chambers 30 min before asenapine or
vehicle administration. For testing with haloperidol, olan-
zapine, and risperidone, rats were administered active
treatment or vehicle immediately before being placed into
the chambers. Thirty minutes after being placed into the
chambers, low- or high-dose D-amphetamine was adminis-
tered. Therefore, D-amphetamine injections were adminis-
tered 30 min after haloperidol, olanzapine, and risperidone
and immediately after asenapine.
Study 2: apomorphine-disrupted prepulse inhibition
Two experiments were conducted to examine the effects of
asenapine on startle and PPI. The first experiment used high
doses of asenapine (0.03–3.0 mg/kg). Based on the effects
of 0.03 and 0.1 mg/kg asenapine in that study, a second was
conducted to replicate these data and to determine the
effects of lower asenapine doses.
Startle magnitude and PPI were assessed using apparatus
(SR-LAB™ Startle System, San Diego Instruments, San
Diego, CA, USA) and procedures similar to those described
in previous studies (Swerdlow et al. 1998; Varty and Geyer
1998). Rats were handled before testing was initiated to
reduce the stress of handling.
Each test was initiated 5 min after the rat was placed
in the chamber, where background white noise (70 dB)
was present during the acclimation period and for the
duration of testing. Each test consisted of a series of
trials, separated by a variable interval averaging 15 s,
with two conditions: (1) presentation of a startle stimulus
(118 dB, 40-ms noise burst) and (2) presentation of the
startle stimulus 100 ms after the presentation of a 20-ms
prepulse at 73, 76, or 82 dB. PPI was defined as the
percentage reduction in startle amplitude in the presence
vs the absence of the prepulse [100–(100×(startle
amplitude on prepulse trial/startle amplitude on startle-
only trial))]. Sessions were divided into four blocks.
Blocks 1 and 4 assessed only startle magnitude in
response to four consecutively presented startle-only
trials. Blocks 2 and 3 each included eight startle-only
trials and five trials with each prepulse type. Stabilimeter
recordings were made between each trial, and the mean
value of these measures was subtracted from startle
values to account for motor artifact.
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drug testing to divide rats into PPI-matched treatment
groups (n=10). All tests took place between 0900 and 1600
hours. Rats were tested according to a predetermined
sequence that counterbalanced treatment groups with
respect to time of day and stabilimeter chamber. For drug
testing, asenapine or vehicle pretreatment occurred 30 min
before apomorphine or vehicle treatment. Rats were placed
into individual startle chambers immediately after receiving
apomorphine or vehicle treatment.
Study 3: delayed non-match to place
Behavior was assessed in operant boxes (Med Associates,
Inc., St. Albans, VT, USA) equipped with two levers, a
house light and cue lights, and a reinforcement magazine
containing a cue light. Magazine entries (i.e., nose pokes)
were monitored by an infrared beam. Operant boxes were
monitored and controlled by Med Associates interfaces
using MED-PC® for Microsoft Windows®, version 1.15
(Med Associates, Inc.).
DNMTP training was conducted in three phases. First,
rats were trained to associate illumination of the magazine
cue light with delivery of a 45-mg food pellet (Noyes
Precision Pellets, Formula P, New Brunswick, NJ, USA).
During the next phase, a single press of the lever whose
associated cue light was illuminated was reinforced. During
the final phase, the DNMTP task was introduced.
During a sample component, rats were required to nose
poke into the food magazine after pressing a randomly
presented lever. The first nose poke occurring after a
variable delay (0.3–30 s) initiated the choice component.
During the choice component, a response on the lever not
presented during the sample component (i.e., a non-match
to place) was reinforced and designated as a correct
response. A response on the sample-component lever (i.e.,
a match to place) was designated as an incorrect response
and was not reinforced. Incorrect responses were followed
by a 3-s timeout. Each session lasted 126 trials or 40 min.
Drug testing was initiated when accuracy, defined as the
percentage of correct responses, was reliably ≥85%.
Criterion levels of performance were attained after no more
than 30 sessions.
Accuracy was the primary performance variable
assessed. Total session accuracy and accuracy at each
delay (short delays, 0.3–3.0 s; long delays, 5.6–30 s)
were transformed using the arcsin square root function
[ASIN(SQRT(((percentage correct/100)−0.5)×2))]. To fa-
cilitate this transformation, accuracy scores <50% were
substituted with a value of 50%. Behavioral latencies,
total trials completed, total session nose pokes, and nose-
poke rates were also examined. To normalize the
distribution of the mean behavioral latencies, these data
were log10 transformed. All rats were included in the
analysis of the total number of trials completed, but only
rats completing ≥28 trials were included in the assessment
of other performance analyses. Because nose-poke rates
during the 0.3- and 1.0-s delay could not be captured, they
were not assessed.
For drug testing, all agents were administered 30 min
before placing the animal in the operant chamber. The
sequence of drug administration followed a Latin square
design, with baseline performance (Monday and Thursday)
assessed the day before drug testing (Tuesday and Friday).
At least 1 day elapsed between drug-test days. All rats
received vehicle and all drug doses. All testing was
performed between 0900 and 1600 hours with a particular
animal's test time never deviating more than plus or minus
30 min across days.
Study 4: five-choice serial reaction task
Behavior was assessed in five-choice operant boxes (Med
Associates, Inc.) that were housed inside ventilated, sound-
attenuating chambers. Each box was equipped with a
stainless steel grid floor and five wall-mounted response
apertures and a reinforcement magazine into which 45-mg
Noyes food pellets could be delivered. Operant boxes were
monitored and controlled as described above.
Rats were first trained to retrieve food pellets from the
illuminated magazine every 15 s during a 10-min session.
During phase 2, a nose poke into the illuminated magazine
initiated a trial. After a 5-s intertrial interval (ITI), all the
response apertures were illuminated, and a nose poke in any
aperture was reinforced. To encourage nose poking, three
pellets were placed into each aperture at the beginning of
each 25-min session.
At the start of each session during the last stage of
training, a nose poke into the magazine initiated the 5-s ITI.
Nose pokes during the ITI were designated premature
responses and initiated a 5-s timeout. If the ITI period ended
without another premature response, a response aperture was
illuminatedinapseudorandom fashionfor10s[i.e.,stimulus
duration (SD) of 10 s]. A nose poke into this aperture within
the SD period or the ensuing 5-s limited hold (LH) was
designated a correct response. A nose poke in any other
aperture was designated an incorrect response. If there was
no response within the SD+LH period, an omission was
recorded. During training, the SD progressively decreased
until an SD of 0.5 s was attained. Drug testing began when
accuracy (i.e., the percentage of correct responses: [(correct/
(correct+incorrect))×100]) averaged >80% and the percent-
age of omissions was <20% for two consecutive days. The
latencies for correct responses, incorrect responses, and
pellet collection were also recorded. Each training session
lasted 30 min or 100 trials.
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the animal in the operant chamber. The sequence of drug
administration followed the same Latin square design
described for the DNMTP studies. All rats received vehicle
and all drug doses. Two task conditions were assessed:
standard (SD=0.5 s) and difficult (SD=0.25 s). Asenapine
(n=12) and olanzapine (n=8) were tested under the
standard and difficult test conditions, whereas risperidone
(n=12) was tested only under difficult test conditions. Test
sessions lasted 45 min or 400 trials. All testing was
performed between 0900 and 1600 hours with a particular
animal’s test time never deviating more than plus or minus
30 min across days.
Statistics
Data were analyzed using one-, two-, or three-way
analysis of variance (ANOVA), with statistical signifi-
cance set at P<0.05. For the Amp-LMA studies, statistical
analyses (Sigmaplot®, Systat Software Inc., San Jose, CA,
USA) consisted of one-way ANOVA, with treatment group
as a between-subject factor; post hoc Dunnett tests were
used to assess dose effects compared with vehicle when
appropriate. For the Apo-PPI studies, statistical analyses
(Systat® and Statview, Systat Software Inc., San Jose, CA,
USA) consisted mixed-design ANOVA. Asenapine pre-
treatment dose (between-subjects factor), apomorphine
treatment (within-subjects factor), and trial blocks and/or
types (repeated measures factors adjusted using
Greenhouse-Geisser or Huynh-Feldt techniques) were in-
cluded in the model. As appropriate, post hoc comparisons
were made using Newman–Keuls, Dunnett, or Tukey tests.
For DNMTP and 5-CSR studies, statistical analyses were
conducted using Minitab release 14 (Minitab Inc., State
College, PA, USA). DNMTP analyses consisted of two-
way (treatment×day) or three-way (treatment×day×delay)
repeated measures ANOVA. 5-CSR analyses consisted of
two-way (treatment×time) repeated measures ANOVA. In
these studies, all factors were treated as within-subject
measures. Post hoc Dunnett tests compared active agent
with vehicle, and main interactions were assessed using
Tukey tests.
Results
Study 1: spontaneous and amphetamine-stimulated
locomotor activity
D-Amphetamine, 1 and 3 mg/kg respectively, stimulated
LMA, with peaks at around 45 and 20 min postdosing
(Fig. 1a, b). Asenapine significantly reversed LMA stimu-
lated by 1 and 3 mg/kg D-amphetamine (Table 1 and
Fig. 1a, b). Post hoc analyses indicated that 0.03 and
0.1 mg/kg asenapine reversed low-dose Amp-LMA and 0.1
and 0.3 mg/kg asenapine reversed high-dose Amp-LMA
(Dunnett tests, all P<0.05 vs vehicle, Table 1). The
minimal effective doses (MEDs) of asenapine (0.03 and
0.1 mg/kg after low- and high-dose D-amphetamine,
respectively) produced 55% and 70% inhibitions of Amp-
LMA, respectively (Table 1).
Spontaneous LMA in vehicle-treated rats was initially
high but rapidly decreased to low levels after 30 min
(Fig. 1c). Asenapine significantly inhibited spontaneous
LMA (Table 1). Post hoc analyses indicated that 0.01–
0.1 mg/kg asenapine reduced spontaneous LMA compared
with vehicle (Dunnett’st e s t s ,a l lP<0.05). The MED of
asenapine for spontaneous LMA (0.01 mg/kg) produced a
25% inhibition (Table 1).
Haloperidol, olanzapine, and risperidone significantly
reduced spontaneous and Amp-LMA (Fig. 2 and
Table 1). Post hoc analysis indicated that only the highest
doses of haloperidol (0.3 and 1.0 mg/kg) and olanzapine
(3.0 and 10.0 mg/kg) reduced LMA compared with
vehicle (Dunnett’s tests, all P<0.05), with neither agent
having a differential MED across test conditions (Table 1).
The percent reductions in LMA for the MED of
haloperidol (0.3 mg/kg) were comparable across D-
amphetamine doses (54.3% and 43.3% reductions after
low- and high-dose D-amphetamine, respectively). In
contrast, reductions in Amp-LMA produced by the MED
of olanzapine (3.0 mg/kg) were more pronounced after
low-dose D-amphetamine compared with high-dose D-
amphetamine (29.9% vs 73.1%). Risperidone significantly
reduced low-dose Amp-LMA after 0.3 and 1.0 mg/kg
(53.4% reduction at MED of 0.3 mg/kg), high-dose Amp-
LMA after 3.0 mg/kg (93.9% reduction), and spontaneous
LMA after 1.0 and 3.0 mg/kg (64.7% reduction at MED
of 1.0 mg/kg).
Study 2: apomorphine-disrupted prepulse inhibition
Significant main effects of asenapine and apomorphine, as
well as statistical interactions with prepulse intensity and
trial block, were reported in the low- and high-dose
experiments (see Table 2). Only post hoc analyses are
summarized below.
Low-dose asenapine
Post hoc analysis revealed that startle magnitude signifi-
cantly increased (P<0.002) in apomorphine-treated rats
pretreated with 0.1 mg/kg asenapine compared with rats
pretreated with vehicle (Fig. 3a). A comparable nonsignif-
icant increase was observed for 0.03 mg/kg asenapine. An
overall habituation effect on startle magnitude between
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(data not shown).
In post hoc analyses restricted to apomorphine-treated
rats, asenapine 0.03 mg/kg (P<0.006) and 0.1 mg/kg (P<
0.0002) reversed apomorphine-induced disruption of PPI
when collapsed across prepulse intensity (Fig. 4a). Asena-
pine 0.01 mg/kg also demonstrated a near-significant effect
(P=0.054). In post hoc analysis restricted to vehicle
pretreated rats and collapsed across prepulse intensity, PPI
was significantly increased after asenapine 0.003 mg/kg
and significantly decreased after 0.1 mg/kg compared with
vehicle (both P<0.05; Fig. 4a).
High-dose asenapine
Asenapine pretreatment (0.03 to 1.0 mg/kg) produced a
trend toward increased startle compared with vehicle
pretreatment. Post hoc analysis of individual doses of
asenapine in vehicle-treated rats demonstrated that
1.0 mg/kg asenapine significantly increased startle
magnitude compared with vehicle pretreatment (P<
0.05, Fig. 3b). In apomorphine-treated rats, 0.03 mg/kg
asenapine significantly increased startle magnitude com-
pared with vehicle pretreatment (P<0.05, Fig. 3b). The
significant apomorphine treatment effect was reflected by
an inverted “U” shaped function of apomorphine on startle
magnitude when data are collapsed across blocks 1 and 4.
An overall habituation effect on startle magnitude between
blocks 1 and 4 was reflected by a main effect of trial block
(data not shown).
Post hoc assessment of apomorphine-treated rats
collapsed across prepulse intensity revealed significant
reversals of apomorphine-induced disruption of PPI with
0.03 mg/kg (P<0.015), 0.1 mg/kg (P<0.0001), and
3.0 mg/kg (P<0.006) asenapine (Fig. 4b). In vehicle-
treated rats, asenapine at 0.1 (P<0.045), 0.3 (P<0.0004),
1.0 (P<0.0015), and 3.0 mg/kg (P<0.015) produced a
significant decrease in PPI when compared with vehicle
(Fig. 4b).
Study 3: delayed non-match to place
Asenapine
Assessment of accuracy reported no significant overall effects
of asenapine (Fig. 5a). Although the treatment×delay interac-
tion was not significant, post hoc analysis reported effects of
asenapine on accuracy during short delays [F(3,96)=12.22,
P<0.001], with 0.1 mg/kg asenapine decreasing accuracy (P<
0.0001 vs vehicle; Fig. 5b). Asenapine did not alter the total
number of trials completed (Table 3).
Significant main effects of asenapine were reported for
correct and incorrect response latencies (Table 3). Post hoc
analysis indicated that 0.1 mg/kg asenapine increased
correct and incorrect response latencies (both P<0.05 vs
vehicle). Asenapine also tended to increase pellet collection
latency. A main treatment effect of asenapine on nose-poke
rate was also found. Post hoc analysis indicated that 0.056
and 0.10 mg/kg asenapine decreased nose-poke rate (P<
0.01 and P<0.001, respectively).
Olanzapine
Assessment of accuracy reported no overall effects of
olanzapine (Fig. 5c). A significant treatment effect [F
(3,84)=3.14, P<0.05] and a treatment×delay interaction
[F(9,84)=2.33, P<0.05] were reported on accuracy at
short delays, but post hoc analyses did not identify
significant differences between olanzapine and vehicle
(Fig. 5d). Olanzapine did not alter the total number of
trials completed (Table 3).
Analysis of response latencies reported main effects of
treatment for correct response latency (Table 3). Post hoc
analysis indicated that 0.5 and 1.0 mg/kg olanzapine
increased correct response latency (both P<0.05 vs vehi-
cle). Olanzapine did not alter the total number of nose
pokes, but nose-poke rate was decreased by olanzapine
with post hoc analysis indicating that 1.0 mg/kg olanzapine
decreased nose-poke rate (P<0.001 vs vehicle).
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locomotor activity (c). D-Amp D-amphetamine, s.c. subcutaneous
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Risperidone decreased overall accuracy [F(3,28)=5.59, P<
0.005], but post hoc assessment did not identify significant
differences between risperidone and vehicle (Fig. 5e). A
significant main effect of risperidone during short delays
was reported [F(3,84)=26.10, P<0.001], with accuracy
being decreased by 0.3 mg/kg risperidone (Dunnett’s test,
P<0.0001 vs vehicle; Fig. 5f). Analysis of longer delays
revealed a treatment×delay interaction [F(9,112)=3.31, P<
0.001]. Post hoc analysis reported that 0.3 mg/kg risper-
idone improved accuracy at the 30-s delay (P<0.05 vs
vehicle; Fig. 5f). Risperidone decreased the total number of
trials completed [F(3,28)=24.80, P<0.001], with total trials
completed being decreased by 0.3 mg/kg risperidone (P<
0.0001 vs vehicle; Table 3).
Analysis of response latencies reported main effects of
risperidone on correct response, incorrect response, and
pellet collection latencies (Table 3). Post hoc analysis
confirmed that 0.3 mg/kg risperidone increased these
Table 1 Inhibition of D-amphetamine-stimulated and spontaneous locomotor activity by asenapine, haloperidol, olanzapine, and risperidone
D-Amphetamine (1mg/kg s.c.) D-Amphetamine (3mg/kg s.c.) Spontaneous LMA
Total distance
traveled (cm)
Reduction from
vehicle (%)
Total distance
traveled (cm)
Reduction from
vehicle (%)
Total distance
traveled (cm)
Reduction from
vehicle (%)
Asenapine (mg/kg s.c.)
Vehicle 27,292±5,863 32,177±3,437 3,033±239
0.01 21,002±2,659
a 23.1±9.7 Not tested 2,268±135* 25.2±4.4
0.03 12,365±1,857* 54.7±6.8 36,670±1,968 –14±6.1 1,780±153* 41.3±5.0
0.1 6,925±1,325* 74.6±4.9 9,596±2,326* 70.2±7.2 311±94* 89.8±3.1
0.3 Not Tested 2,232±5,77* 93.1±1.8 Not tested
F(3,27)=6.95,
P=0.001
F(3,28)=52.89,
P<0.001
F(3,28)=48.92,
P<0.001
Haloperidol (mg/kg oral gavage)
Vehicle 26,279±2,531 37,428±5,016 2,461±262
0.1 20,986±3,596 20.1±13.7 34,616±4,092 7.5±10.9 2,334±239 5.2±9.7
0.3 12,007±2,801* 54.3±10.7 21,210±3,666* 43.3±9.8 1,450±124* 41.1±5.0
1.0 1,438±3,04* 94.5±1.2 4,239±1,116* 88.7±3.0 187±68* 92.4±2.8
F(3,28)=17.97,
P<0.001
F(3,28)=23.02,
P<0.001
F(3,28)=30.18,
P<0.001
Olanzapine (mg/kg oral gavage)
Vehicle 22,597±4,014 49,117±5,052 3,021±435
1.0 30,194±4,524 –33.6±20.0 48,284±4,913 1.7±0.0 2,461±217 18.5±7.2
3.0 6,072±1,524* 73.1±6.8 34,413±4,508* 29.9±9.2 819±113* 72.9±3.8
10.0 184±40* 99.2±0.2 1,400±3,59* 97.2±0.7 42±18* 98.6±0.6
F(3,28)=20.14,
P<0.001
F(3,28)=28.40,
P<0.001
F(3,28)=30.99,
P<0.001
Risperidone (mg/kg oral gavage)
Vehicle 25,280±3,369 36,180±3,364
a 2,780±231
0.1 22,524±4,071 10.9±16.1 Not tested Not Tested
0.3 11,775±1,581* 53.4±6.3 45,354±3,588 –25.4±9.9 2,554±315 8.1±11.4
1.0 4,400±968* 82.6±3.8 26635±2788 26.4±7.7 980±143* 64.7±5.2
3.0 Not tested 2,216±7,17* 93.9±2.0 166±46* 94.0±1.7
F(3,28)=11.95,
P<0.001
F(3,27)=44.43,
P<0.001
F(3,28)=36.10,
P<0.001
Data are mean±SEM (n=8 per dose, except where noted). Percent reduction from vehicle calculated as: [1−(treatment response/vehicle mean
response)]×100; negative values indicate increased LMA
LMA locomotor activity, s.c. subcutaneous.
*P≤0.05 vs vehicle; one-way ANOVA followed by post-hoc Dunnett’s test
aIndicates n=7
Psychopharmacology (2009) 206:699–714 705latencies (all P<0.0001 vs vehicle). Main effects of
risperidone treatment were also reported for total number
of nose pokes and nose-poke rate per second of delay. Post
hoc analysis indicated that 0.3 mg/kg risperidone de-
creased the total number of nose pokes compared with
vehicle (P<0.0001) and 0.1 and 0.3 mg/kg risperidone
decreased nose-poke rate per second delay compared with
vehicle (P<0.01).
Time in Chamber, min
0 10 20 30 40 50 60 70 80 90 100110120
Time in Chamber, min
0 1 02 03 04 05 06 07 08 09 0 1 0 0 1 1 0 1 2 0
Time in Chamber, min
0 1 02 03 04 05 06 07 08 09 0 1 0 0 1 1 0 1 2 0
0 10 20 30 40 50 60 70 80 90 100110120
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000 Ve
Hal
Ha
Time in Chamber, min
0 1 02 03 04 05 06 07 08 09 0 1 0 0 1 1 0 1 2 0
Time in Chamber, min
0 1 02 03 04 05 06 07 08 09 0 1 0 0 1 1 0 1 2 0
Time in Chamber, min
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000
3500 Vehicle p.o. / D-Amp 3 mg/kg s.c.
Haloperidol 0.1 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Haloperidol 0.3 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Haloperidol 1.0 mg/kg p.o. / D-Amp 3 mg/kg s.c.
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000 Vehicle p.o. / D-Amp 1 mg/kg s.c.
Olanzapine 1 mg/kg p.o. / D-Amp 1 mg/kg s.c.
Olanzapine 3 mg/kg p.o. / D-Amp 1 mg/kg s.c.
Olanzapine 10 mg/kg p.o. / D-Amp 1 mg/kg s.c.
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000
3500
4000
4500 Vehicle p.o. / D-Amp 3 mg/kg s.c.
Olanzapine 1 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Olanzapine 3 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Olanzapine 10 mg/kg p.o. / D-Amp 3 mg/kg s.c.
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000 Vehicle p.o. / D-Amp 1 mg/kg s.c.
Risperidone 0.1 mg/kg p.o. / D-Amp 1 mg/kg s.c.
Risperidone 0.3 mg/kg p.o. / D-Amp 1 mg/kg s.c.
Risperidone 1.0 mg/kg p.o. / D-Amp 1 mg/kg s.c.
D
i
s
t
a
n
c
e
 
T
r
a
v
e
l
e
d
,
 
c
m
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000 Vehicle p.o. / D-Amp 3 mg/kg s.c.
Risperidone 0.1 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Risperidone 0.3 mg/kg p.o. / D-Amp 3 mg/kg s.c.
Risperidone 1.0 mg/kg p.o. / D-Amp 3 mg/kg s.c.
A.
B.
C. E.
F. D.
Vehicle oral gavage / D-Amp 1 mg/kg s.c.
Haloperidol 0.1 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Haloperidol 0.3 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Haloperidol 1.0 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Vehicle oral gavage / D-Amp 3 mg/kg s.c.
Haloperidol 0.1 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Haloperidol 0.3 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Haloperidol 1.0 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Vehicle oral gavage / D-Amp 3 mg/kg s.c.
Olanzapine 1 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Olanzapine 3 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Olanzapine 10 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Vehicle oral gavage / D-Amp 1 mg/kg s.c.
Olanzapine 1 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Olanzapine 3 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Olanzapine 10 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Vehicle oral gavage / D-Amp 1 mg/kg s.c.
Risperidone 0.1 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Risperidone 0.3 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Risperidone 1.0 mg/kg oral gavage / D-Amp 1 mg/kg s.c.
Vehicle oral gavage / D-Amp 3 mg/kg s.c.
Risperidone 0.1 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Risperidone 0.3 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Risperidone 1.0 mg/kg oral gavage / D-Amp 3 mg/kg s.c.
Fig. 2 Effects of haloperidol (a, b), olanzapine (c, d), and risperidone (e, f) on locomotor activity stimulated by 1.0or 3.0 mg/kg D-amphetamine.
D-Amp D-amphetamine, s.c. subcutaneous
Table 2 Summary of statistical analyses for asenapine and apomorphine effects on prepulse inhibition
Factor Low-dose Asenapine High dose Asenapine
Startle magnitude Asenapine F(5,54)=2.48, P<0.05 NS
Apomorphine NS F(1,54)=10.62, P<0.002
Asenapine×Apomorphine NS F(5,54)=3.09, P<0.02
Habituation Trial block F(1,54)=67.06, P<0.0001 F(1,54)=80.76, P<0.0001
Apomorphine NS NS
Asenapine×apomorphine F(5,54)=3.37, P<0.02 F(5,54)=3.64, P<0.007
Asenapine×trial block NS F(5,54)=2.76, P<0.03
Asenapine×apomorphine×trial block F(5,54)=3.18, P<0.015 NS
Prepulse inhibition Asenapine F(5,54)=3.01, P<0.02 F(5,54)=3.29, P<0.015
Apomorphine F(1,54)=59.67, P<0.0001 F(1,54)=15.68, P<0.0003
Prepulse intensity F(2,108)=74.32, P<0.0001 F(2,108)=185.35, P<0.0001
Asenapine×apomorphine F(5,54)=8.74, P<0.0001 F(5,54)=9.53, P<0.0001
Asenapine×prepulse intensity F(10,108)=4.54, P<0.001 F(10,108)=3.35, P<0.001
Apomorphine×prepulse intensity F(2,108)=20.02, P<0.0001 F(2,108)=8.39, P<0.0005
Apomorphine×trial block F(1,54)=4.38, P<0.05 NS
Asenapine× ×trial block F(5,54)=4.00, P<0.004 NS
Trial block×prepulse intensity NS F(2,108)=8.41, P<0.0005
Asenapine×apomorphine×prepulse intensity F(10,208)=1.94, P<0.05 NS
Asenapine×prepulse intensity×trial block F(10,108)=2.13, P<0.03 NS
NS not significant
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Standard condition–stimulus duration of 0.5 s
Asenapine Asenapine did not significantly alter perfor-
mance (Table 4).
Olanzapine Main effects of treatment were reported for the
percentage of omissions. Post hoc analyses revealed that
0.3 mg/kg olanzapine increased the percentage of omissions
(P<0.0001 vs vehicle; Table 4).
Difficult condition–stimulus duration of 0.25 s
Asenapine Main effects of treatment on trials completed,
the percentage of omissions, and incorrect response
latency were reported with low-dose asenapine (Table 4).
Post hoc comparisons revealed that 0.03 mg/kg asenapine
decreased total trials completed (P=0.003), increased the
percentage of omissions (P=0.001), and increased incor-
rect response latency (P= 0 . 0 1 1 )c o m p a r e dw i t hv e h i c l e
(Table 4).
Main effects of treatment were reported for trials
completed, the percentages of correct trials and omissions,
and correct and incorrect response latencies with high-dose
asenapine (Table 3). Posthocanalysisrevealedthat0.1mg/kg
asenapine decreased the percentage of correct responses
(P<0.0001 vs vehicle). Both 0.1 and 0.3 mg/kg asenapine
increased the percentage of omissions (P=0.005 and P<
0.0001 vs vehicle, respectively) and decreased total trials
completed (both P<0.0001 vs vehicle). Correct response
and incorrect response latencies were increased by 0.3 mg/
kg asenapine (P<0.0001 and P=0.006, respectively, vs
vehicle). The effects of 0.03 mg/kg asenapine were not
replicated in this experiment.
Olanzapine Main effects of olanzapine were reported for
trials completed, the percentage of correct responses and
omissions, and pellet collection latency (Table 4). Post hoc
comparisons revealed that 0.03 and 0.3 mg/kg olanzapine
reduced the percentage of correct responses (P=0.008 and
P=0.002, respectively, vs vehicle). Both 0.1 and 0.3 mg/kg
olanzapine increased the percentage of omissions (P=0.009
and P<0.0001 vs vehicle, respectively). All olanzapine
doses reduced total trials completed (all P<0.05 vs
vehicle). Despite the significant main effect of treatment
on pellet collection latency, post hoc analysis did not report
significant differences between olanzapine and vehicle.
Risperidone Main effects of treatment were reported for
trials completed, the percentage of omissions, correct and
incorrect response latencies, and pellet collection latency.
Risperidone did not significantly alter the percentage of
correct responses (Table 4). Post hoc comparisons revealed
that 0.03 and 0.1 mg/kg risperidone increased the percent-
age of omissions (both P=0.001 vs vehicle) and reduced
trials completed (both P<0.02 vs vehicle). Incorrect
response latency was increased by 0.03 and 0.1 mg/kg
risperidone (P=0.005 and P<0.0001, respectively, vs
vehicle). Only 0.1 mg/kg risperidone increased correct
response latency (P<0.0001 vs vehicle) and only 0.03 mg/
kg risperidone increased pellet collection latency (P=0.017
vs vehicle).
Discussion
The main findings of the studies described in the current
report are that: (1) asenapine showed highly potent activity
in two independent tests predictive of antipsychotic efficacy
(Amp-LMA and Apo-PPI) and (2) neither asenapine nor the
comparator drugs (olanzapine, risperidone) across a range
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Fig. 3 Effects of low-dose asenapine (a)o rh i g h - d o s ea s e n a p i n e
(b) on average startle magnitude during prepulse trails (blocks 2 and
3). PPI prepulse inhibition, s.c. subcutaneous, Veh vehicle.
†P<0.05
(vehicle pretreatment+apomorphine treatment vs asenapine treat-
ment+apomorphine treatment).
‡P<0.05 (vehicle pretreatment+
vehicle treatment vs asenapine treatment+vehicle treatment)
Psychopharmacology (2009) 206:699–714 707of doses improved performance in cognitive tasks designed
to assess effects on short-term spatial memory and attention
in normal healthy rats. These data further increase the
understanding of the behavioral psychopharmacologic
properties of asenapine.
D-amphetamine-induced hyperactivity and Apo-PPI
(Geyer and Ellenbroek 2003) are two of several behavioral
animal paradigms that are used to detect antipsychotic
activity. The potent reversal of Amp-LMA by asenapine
supports its potential for antipsychotic activity. The potency
of asenapine in this model is also consistent with its high
affinity and antagonistic activity at the dopamine D2
receptor (Shahid et al. 2009). The effects of asenapine in
this study were examined against two doses of D-amphet-
amine based on evidence indicating that low and high doses
of the dopaminergic stimulant show differential sensitivity
of inhibition by different classes of antipsychotic agents
(Arnt and Skarsfeldt 1998). It has been speculated that this
may be partially related to the preferential engagement of
mesolimbic and striatal neuronal pathways by low and high
doses of D-amphetamine, respectively (Arnt 1995). Asena-
pine showed a slightly higher potency for inhibiting the
effects of 1 mg/kg D-amphetamine compared with 3 mg/kg
D-amphetamine. Like asenapine, the effects of risperidone
differed between the two doses of D-amphetamine. In
contrast, haloperidol showed similar potency with both doses
of D-amphetamine. The same could be argued for olanza-
pine, which showed a similar MED of 3 mg/kg against the
A.
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Fig. 4 Effects of low-dose
asenapine (a)o rh i g h - d o s e
asenapine (b) on the inhibition
of PPI induced by apomorphine
collapsed across prepulse in-
tensity and for each prepulse
intensity (inset). PPI prepulse
inhibition, s.c. subcutaneous,
Veh vehicle. *P<0.001; **P<
0.0001 (vehicle pretreatment+
apomorphine treatment vs ve-
hicle pretreatment+vehicle
treatment).
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708 Psychopharmacology (2009) 206:699–714two doses of D-amphetamine. However, it should be noted
that olanzapine did show a much stronger inhibition of 1 mg/
kg D-amphetamine compared with 3 mg/kg D-amphetamine,
with respective reductions compared with vehicle of 73%
and 30%. Thus, overall the current data are consistent with
the findings reported by Arnt (1995).
The ability of second-generation antipsychotics (SGAs)
to differentially reduce hyperactivity induced by low- vs
high-dose D-amphetamine may also be partially attributed
to their antagonism of 5-HT2A receptors (Arnt 1995). It has
been reported that the effects of low-dose, but not high-
dose, D-amphetamine are inhibited by the selective 5-HT2A
antagonists ritanserin and MDL 100,151 (Feldman et al.
1997). Our findings support this hypothesis because the
rank order of MEDs for inhibition of hyperactivity
stimulated by low-dose amphetamine (0.03 mg/kg asena-
pine<0.3 mg/kg risperidone<3.0 mg/kg olanzapine) mir-
rors the affinity of these agents for the 5-HT2A receptor
(asenapine, ki=0.07 nM; risperidone, ki=0.2 nM; olanza-
pine, ki=1.3 nM; Shahid et al. 2009). As with asenapine,
spontaneous LMA in non-habituated rats was inhibited by
olanzapine, risperidone, and haloperidol.
The ability of asenapine to reverse disruptions in PPI
induced by apomorphine is shared by most antipsychotic
drugs (Geyer et al. 2001; Mansbach et al. 1988) and is
primarily attributed to antagonism of D2 receptors. Given
that asenapine has higher affinity for the D2 receptor
(1.3 nM) than olanzapine and risperidone (21 and 6.2 nM,
respectively; Shahid et al. 2009), it is not surprising that the
potency of asenapine in this study was higher than in
previous studies examining the effects of olanzapine and
risperidone. For example, Auclair et al. (2006) reported that
olanzapine and risperidone doses of at least 0.63 mg/kg
were required to reverse deficits in PPI induced by 0.63 mg/
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Fig. 5 Effects of asenapine (a,
b), olanzapine (c, d), and ris-
peridone (e, f) on DNMTP
performance. Data are mean±
SEM. Ase asenapine, DNMTP
delayed non-match to place,
Olan olanzapine, Risp risperi-
done, s.c. subcutaneous.
§P<
0.0001 (Dunnett test vs vehicle)
Psychopharmacology (2009) 206:699–714 709kg apomorphine. In addition, it is important to note that the
reversal of Apo-PPI produced by asenapine occurred at
doses that did not consistently impact overall startle
magnitude, suggesting that nonspecific motor effects did
not influence these results.
Overall, these LMA and PPI data provide additional
preclinical support for the antipsychotic profile of asena-
pine. In a previous report, doses of asenapine ranging
from 0.05 to 0.2 mg/kg s.c. demonstrated dose-dependent
antipsychotic effects, as measured by suppression of the
conditioned avoidance response (Franberg et al. 2008).
The interpretation of these effects in animal models is
further bolstered by the results of a clinical study in
patients with schizophrenia in which asenapine was found
to be effective in the treatment of positive and negative
symptoms (Potkin et al. 2007).
Neither asenapine nor the SGAs tested demonstrated
cognitive-enhancing properties in the DNMTP or 5-CSR
tasks under the test conditions and doses here in normal
rats. Furthermore, high-dose treatment with asenapine,
risperidone, or olanzapine was generally associated with
impaired performance (e.g., reduced accuracy, increased
omissions, and increased response latencies) that may be
associated with impaired motor performance or sedation.
However, it should be noted that there is a somewhat
different pattern of effects between the compounds.
Asenapine significantly reduced spontaneous activity from
the lowest dose tested 0.01 (mg/kg). Although numerically
the effects of 0.01 mg/kg asenapine (2,268 counts)
compared well with those of the other agents tested
(2,334, 2,461, and 2,554 counts for haloperidol, olanzapine,
and risperidone, respectively) at the lowest doses tested,
only intermediate doses of those agents proved to be
effective. However, a different pattern emerges from the
parameters associated with sedation and motivation in the
cognitive tasks (e.g., the percentage of omissions in the 5-
CSR task or correct latency in the DNMTP task).
Asenapine impairs both measures at a dose of 0.1 mg/kg,
a dose that is a log unit higher than the lowest effective
dose for spontaneous locomotion. Olanzapine increases
Table 3 Effects of asenapine, olanzapine, and risperidone on DNMTP performance
Total trials Log CR latency Log IR latency Log CP latency Total nose pokes Nose pokes/second
of delay
Asenapine
(mg/kg s.c.)
Vehicle 109±4 0.25±0.03 0.26±0.04 0.03±0.03 2426±216 1.85±0.09
0.01 112±3 0.24±0.03 0.29±0.03 0.01±0.03 2387±151 1.66±0.07
0.056 109±4 0.31±0.04 0.33±0.05 0.04±0.03 2218±209 1.53±0.09**
0.1 103±3 0.40±0.04* 0.51±0.08* 0.09±0.03 1844±92 1.25±0.05**
F(3,32)=3.39,
P<0.05
F(3,32)=3.63,
P<0.05
NS NS F(3,160)=13.28,
P<0.001
Olanzapine
(mg/kg s.c.)
Vehicle 109±4 0.24±0.01 0.30±0.03 0.03±0.03 2700±243 2.11±0.10
0.1 108±4 0.27±0.02 0.33±0.05 0.04±0.03 2753±241 2.10±0.10
0.5 102±5 0.34±0.03* 0.38±0.05 0.08±0.03 2503±216 1.83±0.08
1.0 93±5 0.41±0.04* 0.48±0.07 0.12±0.33 1916±276 1.38±0.09***
F(3,28)=7.77,
P<0.001
NS NS NS F(3,140)=12.65,
P<0.001
Risperidone
(mg/kg s.c.)
Vehicle 109±4 0.24±0.03 0.32±0.03 0.02±0.03 2654±240 2.10±0.09
0.03 106±3 0.28±0.01 0.48±0.12 0.05±0.03 2616±229 2.02±0.09
0.1 99±4 0.35±0.02 0.38±0.05 0.08±0.03 2266±241 1.68±0.09**
0.3 65±4*** 0.60±0.04*** 0.98±0.09*** 0.24±0.03*** 956±84*** 0.68±0.04**
F(3,28)=31.68,
P<0.001
F(3,28)=13.89,
P<0.001
F(3,28)=12.58,
P<0.001
F(3,28)=11.55,
P<0.001
F(3,140)=52.78,
P<0.001
Data are the mean±SEM
CP collect pellet, CR correct response, DNMTP delayed non-match to place, IR incorrect response, NS not significant, s.c. subcutaneous
*P<0.05, **P≤0.01, ***P<0.0001 (Dunnett test vs vehicle).
710 Psychopharmacology (2009) 206:699–714Table 4 Effects of asenapine and olanzapine on 5-CSR task performance under standard or difficult conditions
Correct (%) Omissions,% Total trials CR latency (ms) IR latency (ms) CP latency (ms)
Standard paradigm
Asenapine
(mg/kg s.c.)
Vehicle 88.3±1.7 8.3±1.5 264±8 527±31 1,099±74 1,655±172
0.003 88.5±1.9 8.7±1.5 264±8 532±40 1,132±101 1,619±135
0.01 88.2±1.6 9.3±2.0 268±8 522±25 1,125±56 1,635±133
0.03 87.9±1.4 10.4±1.9 262±7 532±30 1,066±108 1,644±119
NS NS NS NS NS NS
Olanzapine
(mg/kg s.c.)
Vehicle 86.0±1.5 7.8±0.9 261±9 510±20 1,130±90 1,410±100
0.03 84.1±1.7 6.4±1.1 263±6 510±20 970±80 1,480±110
0.1 86.9±1.8 8.5±0.8 261±9 510±20 1,230±150 1,550±120
0.3 86.9±1.3 15.8±2.1**** 246±10** 520±20 1,510±240**** 1,550±80
NS F(3,133)=18.83,
P<0.0001
F(3,133)=3.40,
P=0.02
NS F(3,133)=958,
P<0.0001
NS
Difficult paradigm
Asenapine
(mg/kg s.c.)
Vehicle 71.0±1.7 13.9±3.6 240±8 480±18 929±57 1,539±109
0.003 71.2±2.6 12.3±3.3 239±8 477±17 927±47 1,508±104
0.01 72.1±2.4 15.1±4.4 242±8 511±26 1,016±58 1,582±104
0.03 72.9±1.3 19.2±5.1*** 224±12** 516±33 1,080±66* 1,558±92
NS F(3,209)=8.14,
P<0.0001
F(3,209)=6.62,
P<0.0001
NS F(3,209)=3.93,
P=0.001
NS
Asenapine
(mg/kg s.c.)
Vehicle 73.6±2.4 12.3±4.4 231±16 507±26 1,019±59 1,561±118
0.03 69.3±2.6 12.9±3.4 230±10 519±15 1,092±52 1,587±122
0.1 65.0±3.2**** 21.9±3.5** 187±13**** 529±24 1,115±71 1,594±115
0.3 66.3±4.2 39.7±5.9**** 97±26**** 521±33*** 1,446±151**** 2,813±1,064
F(3,209)=6.45,
P<0.0001
F(3,209)=40.01,
P<0.0001
F(3,209)=62.69,
P<0.0001
F(3,209)=6.03,
P=0.001
F(3,209)=5.31,
P=0.002
NS
Olanzapine
(mg/kg s.c.)
Vehicle 73.16±1.7 8.9±1.3 251±6 481±21 1,015±97 1,466.3±114
0.03 68.44±1.2** 10.9±1.3 239±7** 517±36 977±81 1,500.1±121
0.1 70.54±2.2 13.7±3.0** 237±13*** 508±35 987±88 1,500.5±117
0.3 67.4±2.2** 17.3±4.4**** 216±15**** 492±25 1,117±88 1,607.1±179
F(3,189)=3.77,
P=0.012
F(3,189)=11.05,
P<0.0001
F(3,189)=15.96,
P<0.0001
NS NS F(3,189)=3.04,
P=0.03
Risperidone (mg/kg s.c.)
Vehicle 71.1±1.8 13.9±3.6 241±8 480±18 929±57 1,539±109
0.01 71.3±2.6 12.3±3.3 239±8 477±17 927±47 1,508±104
0.03 72.1±2.5 15.1±4.4*** 242±8
* 511±26 1,016±58** 1,582±104*
0.1 73.0±1.3 19.2±5.1*** 224±12**** 516±33**** 1,080±66**** 1,558±92
F(3,269)=7.68,
P<0.0001
F(3,269)=6.95,
P<0.0001
F(3,269)=6.15,
P<0.0001
F(3,269)=9.03,
P<0.0001
F(3,269)=2.93,
P=0.034
Standard paradigm: stimulus duration of cue light=0.25 s. Difficult paradigm: stimulus duration of cue light=0.5 s. Data are mean±SEM.
5-CSR 5-choice serial reaction, CP collect pellet, CR correct response, IR incorrect response, s.c. subcutaneous
“”*P<0.05, **P≤0.01, ***P≤0.001, ****P<0.0001 (Dunnett’s test vs vehicle)
Psychopharmacology (2009) 206:699–714 711omissions and correct response latency at 0.1 and 0.5 mg/
kg, respectively. These doses are lower than the dose,
which reduces spontaneous activity (3.0 mg/kg). Simi-
larly, risperidone has deleterious effects on these 5-CSR
and DNMTP performance measures at doses that are
lower than the dose, which impairs spontaneous activity
(0.03 and 0.3 mg/kg, respectively, vs 1.0 mg/kg). Thus,
these effects are generally consistent with previous
reports of the effects of antipsychotics in tasks of
cognitive function in normal adult rats (Didriksen 1995;
Levin and Christopher 2006; Rosengarten and Quarter-
main 2002; Smith et al. 2000; Terry et al. 2003). However,
the different patterns of effect may suggest that high doses
of asenapine begin to impair cognitive task performance
due to motor retardation or sedation. By contrast,
olanzapine and risperidone induce motor and/or motiva-
tional impairment in cognitive tasks at doses that do not
cause locomotor effects, possibly indicating a brady-
phrenic profile at non-sedative doses.
The data from the cognitive tasks suggest that
asenapine, olanzapine, and risperidone each impaired
short-term spatial memory and attention, as measured by
DNMTP and 5-CSR performance, respectively. Howev-
er, the effects of asenapine on performance were less
pronounced than those of olanzapine and risperidone. In
contrast to olanzapine, asenapine did not induce any
cognitive impairment in the standard version of the 5-
CSR task. When the demand of the task was increased,
cognitive impairment was observed most consistently
after administration of higher asenapine doses (0.1 and
0.3 mg/kg), whereas impairment was observed after
olanzapine and risperidone doses as low as 0.03 mg/kg.
Although the exact mechanism underlying the difference
between asenapine and the other agents requires further
investigation, it is hypothesized that it may be related to
differences in their overall receptor-binding profile and
in particular to antagonism at 5-HT6 and histamine H1
receptors. Asenapine (ki, 0.25 nM) has much higher 5-HT6
receptor affinity than risperidone (ki, 2,187 nM; Shahid et
al. 2009). This difference could be of relevance as
antagonism at the 5-HT6 receptor, with selective ligands
such as SB-399885 and SB-271046, has cognitive-
enhancing effects in animal models (Hatcher et al. 2005;
Hirst et al. 2006). Although olanzapine, similar to
asenapine, has a 6-fold higher affinity for 5-HT6 (ki,
3.2 nM) compared to D2 receptors (ki, 20 nM), the relative
affinity of olanzapine for the H1 receptor over the D2 is
higher than that of asenapine (6- vs 1.3-fold; Shahid et al.
2009). Given that strong H1 receptor antagonism is
associated with sedation (Miller 2004), it could be this
aspect in the differential pharmacologies that contributes
to the difference observed between asenapine and olanza-
pine in the cognition tests used in the current study. In
short, all three of the drugs examined in this study have
complex and varied pharmacologies. The subtle interac-
tion between these various components in each different
scenario makes it difficult to attribute these effects on the
affinity at any one given receptor. Similarly, caution must
be exercised in making an a priori prediction on
performance in a particular task based purely on knowl-
edge of individual receptor affinities.
Previous reports have demonstrated that atypical
antipsychotics routinely reverse cognitive deficits in-
duced by different experimental manipulations (Abdul-
Monim et al. 2003, 2006; Idris et al. 2005;M a r c u se ta l .
2005;T e r r a n o v ae ta l .2005) but rarely improve cognitive
performance in healthy rats (Wolff and Leander 2003). A
number of reports have demonstrated the reversal of
cognitive deficits in reversal learning in rats using
experimental procedures (i.e., phencyclidine- or
amphetamine-induced deficits) relevant to psychiatric
disease (Abdul-Monim et al. 2003, 2006; Idris et al.
2005; Neill et al. 2008). Therefore, it would appear that, as
in humans, these agents are either neutral or deleterious to
cognitive function in healthy individuals, whereas
improvements may be observed in impaired individuals.
In this regard, recent pre-clinical data has indicated that
asenapine can attenuate experimentally induced cognitive
deficits inrodents (Neill etal.2006, 2008;T a i te ta l .2009),
and primates (Jentsch et al. 2006). These pre-clinical data
mirrored the preliminary findings of a clinical study
performed in schizophrenic patients (Fleming et al. 2007).
In conclusion, the reversal of amphetamine-induced
hyperactivity and apomorphine-induced impairments in
PPI by asenapine provides support for antipsychotic
properties and utility in the treatment of schizophrenia
(Potkin et al. 2007). In contrast, the lack of improve-
ment in DNMTP and 5-CSR performance following
treatment with asenapine, olanzapine, or risperidone
suggests that these agents do not have cognitive-
enhancing effects in healthy adult rats. This finding
may indicate the need to move to studies based upon
experimentally induced impairments (Abdul-Monim et
al. 2003, 2006;B i r r e l la n dB r o w n2000; Idris et al. 2005;
Marcus et al. 2005; Terranova et al. 2005)i no r d e rt o
determine if there is potential for clinical utility in the
cognitive domain.
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